50 results on '"Bonaldo, A."'
Search Results
2. WITHDRAWN: Autosomal recessive Bethlem myopathy: A clinical, genetic and functional study
3. 212th ENMC International Workshop
4. 240th ENMC workshop: The involvement of skeletal muscle stem cells in the pathology of muscular dystrophies 25–27 January 2019, Hoofddorp, The Netherlands
5. WITHDRAWN: Autosomal recessive Bethlem myopathy: A clinical, genetic and functional study
6. Transcriptomics analysis in collagen VI myopathy: Role of circadian genes using novel fluidic card tools
7. Transcriptomics analysis in collagen VI myopathy: Role of circadian genes using novel fluidic card tools
8. 212th ENMC International Workshop
9. P5 Detection of circulating miRNAs in serum in a mouse model of Collagen VI Deficiency
10. P5 Detection of circulating miRNAs in serum in a mouse model of Collagen VI Deficiency
11. S.O.6 - Transcriptomics analysis in collagen VI myopathy: Role of circadian genes using novel fluidic card tools
12. 212th ENMC International Workshop:: Animal models of congenital muscular dystrophies, Naarden, The Netherlands, 29–31 May 2015
13. G.P.1.04 Design of a novel array-CGH to explore allelic and genetic heterogeneity in COLVI related myopathies
14. P.1.8 Genetic ablation of p66Shc rescues functional and morphological abnormalities in collagen VI dystrophic mice
15. P.1.8 Genetic ablation of p66Shc rescues functional and morphological abnormalities in collagen VI dystrophic mice
16. G.P.15 Whole transcriptome expression profiling in COL6a1 null mice shows deregulation of circadian clock genes as exploratory COL6 myopathies biomarkers
17. T.P.22 Nanoparticles as delivery systems for antisense oligoribonucleotides: Biodistribution studies and definition of the release kinetic in treated mdx mice
18. P4.50 Mitochondrial therapy with Cyclosporine A in patients with Ullrich Congenital Muscular Dystrophy
19. O.17 Autophagy thwarts collagen VI muscular dystrophies
20. P1.52 BIO-NMD: Discovery and validation of biomarkers for neuromuscular diseases (NMDs) – An EU funded FP7 project
21. P2.3 Monoamine oxidase inhibitors reduce mitochondrial ROS accumulation and dysfunction in patients with collagen VI myopathies
22. O.14 Biocompatible nanoparticles as slow-release delivery system of 2′OMePS AON administered both intraperitoneally and orally in the mdx mice: dystrophin rescue and nanoparticles biodistribution
23. O.17 Autophagy thwarts collagen VI muscular dystrophies
24. P2.3 Monoamine oxidase inhibitors reduce mitochondrial ROS accumulation and dysfunction in patients with collagen VI myopathies
25. P4.50 Mitochondrial therapy with Cyclosporine A in patients with Ullrich Congenital Muscular Dystrophy
26. EM.P.5.07 Abnormal elastin deposits and altered organization of elastic fibers in collagen VI- related disorders
27. EM.I.2 Toward a mitochondrial therapy of collagen VI muscular dystrophies
28. EM.P.5.01 Gene expression and proteome profiles in Col6a1−/− mice, a model of Ullrich congenital muscular dystrophy (UCMD)
29. EM.P.5.04 Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice
30. EM.P.4.09 Immunofluorescence and morphological alterations of capillary wall in skeletal muscle of two myosclerosis myopathy patients
31. EM.P.5.06 Collagen VI alpha5 chain exhibits a restricted localization at junctions in human skeletal muscle and skin
32. EM.P.5.02 Role of mitochondria in the pathogenesis of muscular dystrophies
33. EM.P.4.07 Autosomal recessive Bethlem myopathy
34. EM.P.4.03 Extensive sequencing of COL6A genes in a cohort of 65 patients with collagen type VI related myopathies. Focus on splicing mutations causing Ullrich congenital muscular dystrophy
35. M.P.1.01 Pilot trial with cyclosporin A in patients with collagen VI myopathies
36. EM.P.5.03 The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1-/- myopathic mice
37. EM.P.5.08 Novel collagen VI alpha chains distribution in murine skeletal muscle: Possible implications for neuromuscular disorders
38. G.P.1.04 Design of a novel array-CGH to explore allelic and genetic heterogeneity in COLVI related myopathies
39. T.P.2.07 The systemic administration of a low dose of 2OMePS-AON combined with novel cationic polymethylmethacrylate nanoparticles induces the rescue of dystrophin expression in the mdx murine model
40. EM.P.5.08 Novel collagen VI alpha chains distribution in murine skeletal muscle: Possible implications for neuromuscular disorders
41. EM.P.5.06 Collagen VI alpha5 chain exhibits a restricted localization at junctions in human skeletal muscle and skin
42. EM.I.2 Toward a mitochondrial therapy of collagen VI muscular dystrophies
43. EM.P.4.09 Immunofluorescence and morphological alterations of capillary wall in skeletal muscle of two myosclerosis myopathy patients
44. EM.P.5.01 Gene expression and proteome profiles in Col6a1−/− mice, a model of Ullrich congenital muscular dystrophy (UCMD)
45. EM.P.5.04 Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice
46. EM.P.5.02 Role of mitochondria in the pathogenesis of muscular dystrophies
47. T.P.2.07 The systemic administration of a low dose of 2OMePS-AON combined with novel cationic polymethylmethacrylate nanoparticles induces the rescue of dystrophin expression in the mdx murine model
48. Bethlem myopathy (BETHLEM) and Ullrich scleroatonic muscular dystrophy: 100th ENMC International Workshop, 23–24 November 2001, Naarden, The Netherlands
49. EM.P.5.03 The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1[formula omitted] myopathic mice
50. P.1.8 Genetic ablation of p66Shc rescues functional and morphological abnormalities in collagen VI dystrophic mice.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.